Science News
from research organizations

Entolimod may be a promising treatment option for many solid tumors

Date:
May 29, 2015
Source:
Roswell Park Cancer Institute
Summary:
The first clinical study of the anticancer effects of the novel agent entolimod are now available. Findings confirm preclinical evidence that the agent, which is derived from salmonella flagellin, is worthy of further investigation as treatment for some of the most common and most resilient solid-tumor cancers.
Share:
FULL STORY

A collaborative team of researchers led by Alex A. Adjei, MD, PhD, FACP, of Roswell Park Cancer Institute (RPCI) will share results from the first clinical study of the anticancer effects of the novel agent entolimod at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting in Chicago. Their findings confirm preclinical evidence that the agent, which is derived from salmonella flagellin, is worthy of further investigation as treatment for some of the most common and most resilient solid-tumor cancers.

Toll-like receptors are a family of proteins that help generate immune responses against cancer and other pathogens. Entolimod, the lead drug candidate of Cleveland BioLabs Inc., of Buffalo, N.Y., activates toll-like receptor 5 (TLR5) and has been shown to have immunotherapeutic effects in preclinical cancer models.

Hatoon Bakhribah, MD, a Drug Development Fellow in Roswell Park's Department of Medicine, will present results of this phase I clinical study at ASCO. Dr. Adjei and colleagues evaluated the agent's safety, tolerability, pharmacokinetics, immunoactivity and preliminary antitumor activity in patients with a number of different advanced cancers, including colorectal, non-small-cell lung, anal and urothelial bladder tumors.

Among 26 participants in this dose-escalation study, eight patients had stable disease for more than six weeks following treatment with entolimod, and three patients maintained disease stability for longer than 12 weeks. The tolerability profile in patients with advanced cancer was similar to that observed in two previous studies in 150 healthy volunteers who received entolimod in a similar dose range. Mild-to-severe but manageable side effects such as hypotension and hyperglycemia, all of them anticipated effects of TLR5 activation, were observed in several patients. The results corroborated preclinical findings and suggest that entolimod should be further studied as an immunotherapeutic anticancer agent.

"Our findings are encouraging, as they suggest that entolimod can be safely combined with other chemotherapeutic, targeted or immunotherapeutic agents as treatment for advanced and very hard-to-treat cancers," notes Dr. Adjei, who is Senior Vice President of Clinical Research and the Katherine Anne Gioia Chair in Cancer Medicine at Roswell Park. "We've identified a recommended dosing schedule for future studies."

The study, "A phase I study of the toll-like receptor 5 (TLR5) agonist, entolimod, in patients with advanced cancers," is abstract 3063 and will be presented on board no. 389 during the Developmental Therapeutics -- Immunotherapy poster session on Saturday, May 30.


Story Source:

Materials provided by Roswell Park Cancer Institute. Note: Content may be edited for style and length.


Cite This Page:

Roswell Park Cancer Institute. "Entolimod may be a promising treatment option for many solid tumors." ScienceDaily. ScienceDaily, 29 May 2015. <www.sciencedaily.com/releases/2015/05/150529100954.htm>.
Roswell Park Cancer Institute. (2015, May 29). Entolimod may be a promising treatment option for many solid tumors. ScienceDaily. Retrieved May 23, 2017 from www.sciencedaily.com/releases/2015/05/150529100954.htm
Roswell Park Cancer Institute. "Entolimod may be a promising treatment option for many solid tumors." ScienceDaily. www.sciencedaily.com/releases/2015/05/150529100954.htm (accessed May 23, 2017).

RELATED STORIES